BJMO - 2025, issue SPECIAL, june 2025
Els Dewulf MSc
Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy characterised by rapid growth, high metastatic potential, and poor prognosis. Despite historically limited progress, recent advances in immunotherapy and targeted agents have reshaped the treatment landscape. This article provides an overview of current standards and emerging strategies to improve outcomes for patients with ES-SCLC. The article is limited to systemic therapy and does not address the role of radiotherapy.
Read moreBJMO - 2025, issue SPECIAL, june 2025
Els Dewulf MSc
Over the past decade, the identification of actionable oncogenic driver alterations has revolutionised the treatment landscape of advanced non-small cell lung cancer (NSCLC). Among these, rearrangements involving the anaplastic lymphoma kinase (ALK) gene, or ALK fusions, have emerged as a distinct molecular subset, primarily affecting younger patients with little or no smoking history. The development of ALK tyrosine kinase inhibitors (TKIs) has led to remarkable improvements in clinical outcomes, particularly compared to conventional chemotherapy. More recently, the role of ALK inhibition has also expanded into the adjuvant setting for patients with resectable disease. This article provides an up-to-date overview of the evolving therapeutic landscape for ALK-positive NSCLC.
Read moreBJMO - 2025, issue SPECIAL, june 2025
Els Dewulf MSc
Over the past few years, immunotherapy has radically changed the management of advanced non-small cell lung cancer (NSCLC). More recently, this paradigm shift has extended into early-stage resectable disease. A series of landmark trials have demonstrated that the addition of immune checkpoint inhibitors (ICIs) in the perioperative setting, i.e. both before (neoadjuvant) and after (adjuvant) surgery, can significantly improve long-term outcomes. This article reviews the latest evidence supporting perioperative immunotherapy in resectable NSCLC.
Read moreBJMO - 2025, issue Special, january 2025
Els Dewulf MSc
The 27th annual BSMO (Belgian Society of Medical Oncology) meeting kicked off with the Breast Cancer Task Force. Dr. Yannick Van Herck (University Hospitals Leuven) started the session with a presentation on early recurrence to (neo)adjuvant systemic therapy in triple-negative breast cancer (TNBC). Next, Dr. Andrea Gombos (Institute Jules Bordet) discussed the occurrence of resistance to cyclin dependent kinase 4/6 inhibitors (CDK4/6i) in luminal breast cancer and the optimal treatment choice following CDK4/6i. Finally, Dr. Eline Naert (UZ Ghent) explored the utility of gene expression profiling (GEP) in clinical practice.
Read moreBJMO - 2025, issue Special, january 2025
Els Dewulf MSc
During the 2025 annual BSMO meeting, an entire session was dedicated to the recent advances in rare cancers. In a first lecture of the session, Dr. Patrick Schöffski (University Hospitals Leuven) selected highlights on sarcoma. Next, Dr. Willem Lybaert (VITAZ/UZA) summarised the latest clinical updates in the treatment of neuroendocrine tumours. Finally, Dr. Pierre Frères (CHU de Liège) provided an overview of the latest findings in the management of glioblastoma.
Read moreBJMO - 2025, issue Special, january 2025
Els Dewulf MSc
During the 27th annual BSMO meeting, Prof. Dr. Bertrand Tombal (Cliniques universitaires Saint-Luc) gave his view on future treatments and strategies within genitourinary (GU) malignancies, focusing on urothelial and prostate cancer. He noted that many of the drugs or combinations discussed may not be approved by EMA or reimbursed by RIZIV/INAMI.
Read moreBJMO - 2025, issue Special, january 2025
Els Dewulf MSc
During the academic session of the BSMO 2025 annual meeting, Dr. Matteo Lambertini (University of Genova – IRCCS Ospedale Policlinico San Martino, Italy) talked about the challenges and opportunities in the care of young patients with cancer, particularly young women with breast cancer. Dr. Martine Piccart (Institute Jules Bordet, Belgium) elaborated on the use of surrogate endpoints and the ESMO-MCBS for drug approval.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
